Audiological

The ototoxicity of platinum compounds is well described and is more common with cisplatin (CDDP) than with carboplatin (Piel et al. 1974; Schell et al. 1989; Skinner et al. 1990). Platinum compounds are key components of the chemotherapeutic regimens for high-risk neuroblastoma, and many protocols included dose-intensive cisplatin or carboplatin (Kush-ner et al. 1994; Matthay et al. 1999; Cheung et al. 2001). The overall incidence of cisplatin-induced hearing loss in the pediatric cancer population, including neuroblastoma patients, ranges from 20 to 80% (Schell et al. 1989; Skinner et al. 1990; Weatherly et al. 1991; Parsons et al. 1998; Simon et al. 2002). The hearing loss is more pronounced in the high-frequency

Table 18.1. Clinical and treatment characteristics of neuroblastoma survivors followed in the Long-Term Follow-Up Clinic at MSKCC (n=65). ABMT Autologous bone marrow transplantation, TBI total-body irradiation

Characteristic

No. of patients

Percentage

Gender

Hearing Aids Inside Out

Hearing Aids Inside Out

Have you recently experienced hearing loss? Most probably you need hearing aids, but don't know much about them. To learn everything you need to know about hearing aids, read the eBook, Hearing Aids Inside Out. The book comprises 113 pages of excellent content utterly free of technical jargon, written in simple language, and in a flowing style that can easily be read and understood by all.

Get My Free Ebook


Post a comment